Vnitr Lek 2012, 58(7-8):224-227

Farmacotherapy of hypertension after heart transplantation

L. ©pinarová*, P. Hude, J. Krejčí, H. Poloczková, J. Godava, J. Vítovec
I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny - ICRC Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC

Heart transplantation is now used for the treatment of severe heart failure. In a long-term patient follow-up, hypertension has been identified as a complication. Incidence of hypertension in patients treated with cyclosporine and prednisone is between 70-90%. Besides the traditional mechanisms (renin-angiotensin system, fluid volume and peripheral resistance), aetiology of hypertension includes negative effect of cardiac denervation, cyclosporine immunosuppression, administration of corticosteroids and nephropathy. There is no night drop in the blood pressure and heart rate. Treatment aims to maintain cyclosporine level as low as possible and, if feasible, to discontinue steroids during the first year. Hypertension is usually treated with a combination therapy. Our own observations suggest that the majority of post-transplantation patients have a dual therapy. Calcium channel blockers should be the treatment of choice as they also have an effect on graft vasculopathy. Angiotenzin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), beta-blockers and diuretics are also recommended. Long-acting products should be preferred.

Keywords: heart transplantation; hypertension; pharmacotherapy

Received: May 22, 2012; Published: July 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinarová L, Hude P, Krejčí J, Poloczková H, Godava J, Vítovec J. Farmacotherapy of hypertension after heart transplantation. Vnitr Lek. 2012;58(7-8):224-227.
Download citation

References

  1. Hoąková L, Podzimková M, Málek I et al. Specifika péče o nemocné po transplantaci srdce. Cor Vasa 2011; 53: 60-67.
  2. ©pinarová L. Transplantace srdce. Cor Vasa 2008; 50: 133-138. Go to original source...
  3. Wagoner LE. Management of the cardiac transplant recipient: roles of the transplant cardiologist and primary care physician. Am J Med Sci 1997; 314: 173-184. Go to original source...
  4. Sánchez Lázaro IJ, Bonet LA, Martínez-Dolz L et al. Hypertension after heart transplantation: predictive factors and classes of drugs for its management. Transpl Proc 2008; 40: 3051-3052. Go to original source... Go to PubMed...
  5. Singer DRJ, Jenkins GH. Hypertension in transplant recipients. J Hum Hypertens 1996; 10: 395-402. Go to PubMed...
  6. Ventura HO, Mehra MR, Stapleton DD et al. Cyclosporine-induced hypertension in cardiac transplantation. Med Clin North Am 1997; 81: 1347-1357. Go to original source... Go to PubMed...
  7. Ventura HO, Malik FS, Mehra MR et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997; 12: 375-381. Go to original source... Go to PubMed...
  8. Lanuza D, Grady K, Hetfleisch M et al. Circadian rhythm changes in blood pressure and heart rate during the first year after heart transplantation. J Heart Lung Transplant 1994; 13: 614-623.
  9. Vítovec J, ©pinar J. Vliv ramiprilu na metabolické, renální a srdeční funkce u hypertenze a diabetes mellitus 2. typu. Vnitř Lék 1998; 44: 336-341. Go to PubMed...
  10. Lucini D, Milani RV, Ventura HO et al. Cyclosporine-induced hypertension: evidence for maintaned baroreflex circulatory control. J Heart Lung Transplant 1997; 16: 615-620.
  11. Braith RW, Mills RM Jr, Wilcox C et al. Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients. J Am Coll Cardiol 1996; 27: 375-383. Go to original source... Go to PubMed...
  12. Braith RW, Mills RM Jr, Wilcox C et al. Fluid homeostasis after heart transplantation: the role of denervation. J Heart Lung Transplant 1996; 15: 872-880.
  13. European FK 506 Multicentre Study Group. Randomised trial comparing tacrolimus (FK506) to cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344: 423-428.
  14. Mayer A, Dmitrewski J, Squifflet J et al. Multicenter randomised trial comparing tacrolimus (FK 506) and cyclosporine in prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443. Go to original source... Go to PubMed...
  15. Pirsch JD, Miller J, Deierholi M et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppresion after cadaveric renal transplantation: FK506 Kidney Transplant Study Group. Transplant 1997; 63: 977-983. Go to original source... Go to PubMed...
  16. MacDonald AS. Impact of immunosuppressive therapy on hypertension. Transplantation 2000; 70 (11 Suppl): S70-S76.
  17. ©pinar J, Souček M. Přehodnocení doporučení pro diagnostiku a léčbu hypertenze. Vnitř Lék 2010; 56: 157-161. Go to PubMed...
  18. Schroeder JS, Gao SZ, Aldermann EL et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328: 164-170. Go to original source... Go to PubMed...
  19. Krejčí J, Hude P, ©pinarová L et al. Transplantace srdce - indikace, komplikace, terapie - naąe zkuąenosti ze sledování 100 pacientů po srdeční transplantaci. Vnitř Lék 2000; 46: 750-755. Go to PubMed...
  20. Brozena SC, Johnson MR, Ventura HO et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail. J Am Coll Cardiol 1996; 27: 1707-1712. Go to original source... Go to PubMed...
  21. Schwitzer GK, Hartmann A, Kober G et al. Chronic angiotensin-converting enzyme inhibition may improve sodium excretion in cardiac transplant hypertension. Transplantation 1995; 59: 999-1004. Go to original source... Go to PubMed...
  22. Almenar L, Osa A, Palencia M et al. Effects of fosinopril on the blood pressure and lipid profile of patients undergoing heart transplantation. J Heart Lung Transplant 1997; 16: 454-459.
  23. Midtvedt K, Neumayer HH. Management strategies for posttransplant hypertension. Transplantation 2000; 70 (11 Suppl): S64-S69.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.